Abstract
Stem cells are the core of tissue repair and regeneration, and a promising cell source for novel therapies. In recent years, research into stem cell therapies has been particularly exciting in China. The remarkable advancements in basic stem cell research and clinically effective trials have led to fresh insights into regenerative medicine, such as treatments for sweat gland injury after burns, diabetes, and liver injury. High hopes have inspired numerous experimental and clinical trials. At the same time, government investment and policy support of research continues to increase markedly. However, numerous challenges must be overcome before novel stem cell therapies can achieve meaningful clinical outcomes.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Longstaff H, Khramova V, Eijkholt M, Mizgalewicz A, Illes J. Hopes and fears for professional movement in the stem cell community. Cell Stem Cell, 2013, 12: 517–519
Jin X, Zheng L, Zheng RH, Li YM. China’s policies on stem cell research: an opportunity for international collaborations. Nat Rev Mol Cell Biol, 2009, 10: 286
Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, Lin S, Sun JP. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol, 2004, 94: 92–95
Sheng Z, Fu X, Cai S, Lei Y, Sun T, Bai X, Chen M. Regeneration of functional sweat gland-like structures by transplanted differentiated bone marrow mesenchymal stem cells. Wound Repair Regen, 2009, 17: 427–435
Li Q, Zhou X, Shi Y, Li J, Zheng L, Cui L, Zhang J, Wang L, Han Z, Han Y, Fan D. In vivo tracking and comparison of the therapeutic effects of MSCs and HSCs for liver injury. PLoS ONE, 2013, 8: e62363
Li L, Zhang Y, Li Y, Yu B, Xu Y, Zhao S, Guan Z. Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol-induced global heart failure. Transpl Int, 2008, 21: 1181–1189
Jiang R, Han Z, Zhuo G, Qu X, Li X, Wang X, Shao Y, Yang S, Han ZC. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Front Med, 2011, 5: 94–100
Peng L, Xie DY, Lin BL, Liu J, Zhu HP, Xie C, Zheng YB, Gao ZL. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology, 2011, 54: 820–828
Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. N Engl J Med, 2006, 355: 1730–1735
Daley GQ. The promise and perils of stem cell therapeutics. Cell Stem Cell, 2012, 10: 740–749
Clements WK, Traver D. Signalling pathways that control vertebrate haematopoietic stem cell specification. Nat Rev Immunol, 2013, 13: 336–348
Leventhal J, Miller J, Abecassis M, Tollerud DJ, Ildstad ST. Evolving approaches of hematopoietic stem cell-based therapies to induce tolerance to organ transplants: the long road to tolerance. Clin Pharmacol Ther, 2013, 93: 36–45
Thomas ED. Bone marrow transplantation from the personal viewpoint. Int J Hematol, 2005, 81: 89–93
Griffin M, Iqbal SA, Bayat A. Exploring the application of mesenchymal stem cells in bone repair and regeneration. J Bone Joint Surg Br, 2011, 93: 427–434
Wen Z, Zheng S, Zhou C, Wang J, Wang T. Repair mechanisms of bone marrow mesenchymal stem cells in myocardial infarction. J Cell Mol Med, 2011, 15: 1032–1043
Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res, 2008, 103: 1204–1219
Menasche P. Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol, 2011, 50: 258–265
Williams AR, Trachtenberg B, Velazquez DL, McNiece I, Altman P, Rouy D, Mendizabal AM, Pattany PM, Lopera GA, Fishman J, Zambrano JP, Heldman AW, Hare JM. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res, 2011, 108: 792–796
Ogawa M, LaRue AC, Mehrotra M. Hematopoietic stem cells are pluripotent and not just “hematopoietic”. Blood Cells Mol Dis, 2013, 51: 3–8
Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, Jacobsen N, Ruutu T, de Lima M, Finke J, Frassoni F, Gluckman E. Acute Leukemia Working Party of European Blood and Marrow Transplant Group; Eurocord-Netcord Registry. Transplants of umbilicalcord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med, 2004, 351: 2276–2285
Copeland N, Harris D, Gaballa MA. Human umbilical cord blood stem cells, myocardial infarction and stroke. Clin Med, 2009, 9: 342–345
Harris DT. Non-haematological uses of cord blood stem cells. Br J Haematol, 2009, 147: 177–184
McKenna D, Sheth J. Umbilical cord blood: current status & promise for the future. Indian J Med Res, 2011, 134: 261–269
Prasad VK, Kurtzberg J. Umbilical cord blood transplantation for non-malignant diseases. Bone Marrow Transplant, 2009, 44: 643–651
Trounson A, Thakar RG, Lomax G, Gibbons D. Clinical trials for stem cell therapies. BMC Med, 2011, 9: 52
Taylor CJ, Bolton EM, Bradley JA. Immunological considerations for embryonic and induced pluripotent stem cell banking. Philos Trans R SocLond B Biol Sci, 2011, 366: 2312–2322
Schwartz SD, Hubschman JP, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, Mickunas E, Gay R, Klimanskaya I, Lanza R. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet, 2012, 379: 713–720
Wilson JM. Medicine. A history lesson for stem cells. Science, 2009, 324: 727–728
Lutolf MP, Gilbert PM, Blau HM. Designing materials to direct stem-cell fate. Nature, 2009, 462: 433–441
Mooney DJ, Vandenburgh H. Cell delivery mechanisms for tissue repair. Cell Stem Cell, 2008, 2: 205–213
Trounson A, DeWitt ND, Feigal EG. The Alpha Stem Cell Clinic: a model for evaluating and delivering stem cell-based therapies. Stem Cells Transl Med, 2012, 1: 9–14
Weissman I. Stem cell therapies could change medicine... if they get the chance. Cell Stem Cell, 2012, 10: 663–665
Bianco P, Barker R, Brüstle O, Cattaneo E, Clevers H, Daley GQ, De Luca M, Goldstein L, Lindvall O, Mummery C, Robey PG, Sattler de Sousa E Brito C, Smith A. Regulation of stem cell therapies under attack in Europe: for whom the bell tolls. EMBO J, 2013, 32: 1489–1495
von Tigerstrom B. Product regulation and the clinical translation of stem cell research. Stem Cell Rev, 2009, 5: 135–139
Zarzeczny A, Caulfield T. Stem cell tourism and doctors’ duties to minors—a view from Canada. Am J Bioeth, 2010, 10: 3–15
Hyun I, Lindvall O, Ahrlund-Richter L, Cattaneo E, Cavazzana-Calvo M, Cossu G, De Luca M, Fox IJ, Gerstle C, Goldstein RA, Hermerén G, High KA, Kim HO, Lee HP, Levy-Lahad E, Li L, Lo B, Marshak DR, McNab A, Munsie M, Nakauchi H, Rao M, Rooke HM, Valles CS, Srivastava A, Sugarman J, Taylor PL, Veiga A, Wong AL, Zoloth L, Daley GQ. New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell, 2008, 3: 607–609
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at springerlink.fh-diploma.de
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Huang, S., Fu, X. Stem cell therapies and regenerative medicine in China. Sci. China Life Sci. 57, 157–161 (2014). https://doi.org/10.1007/s11427-014-4608-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-014-4608-3